Evidence map›Paper›PMID 34024853›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.

Ayami Nonomura, Akihiro Tamori, Hoang Hai, Ritsuzo Kozuka, Hideki Fujii, Sawako Uchida-Kobayashi, Masaru Enomoto, Norifumi Kawada

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ayami NonomuraDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Akihiro TamoriDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Hoang HaiDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Ritsuzo KozukaDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Hideki FujiiDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Sawako Uchida-KobayashiDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Masaru EnomotoDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Norifumi KawadaDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glecaprevir/pibrentasvir (GLE/PIB) is a pan-genotype anti-hepatitis C virus (HCV) therapy with high efficacy and safety. However, evidence supporting retreatment following failure of the GLE/PIB regimen is limited. We herein report 3 non-cirrhotic cases involving two men aged 51 and 58 years old and a woman aged 68 years old infected with HCV genotype 1a, 2a, and 3b respectively who failed anti-HCV therapies including GLE/PIB therapy. With combination therapy of sofosbuvir/velpatasvir plus ribavirin (SOF/VEL+RBV) for 24 weeks, all 3 patients had achieved a sustained viral response (SVR) at 24 weeks after completing treatment. SOF/VEL+RBV therapy was effective for retreatment of HCV after failure of GLE/PIB therapy.

Indexed as

Hepatitis C, ChronicSofosbuvirAgedAminoisobutyric AcidsAntiviral AgentsBenzimidazolesBenzopyransCarbamatesCyclopropanesDrug Therapy, CombinationFemaleGenotypeHepacivirusHeterocyclic Compounds, 4 or More RingsHumansLactams, MacrocyclicAminoisobutyric AcidsAntiviral AgentsBenzimidazolesBenzopyransCarbamatesCyclopropanesglecaprevirHeterocyclic Compounds, 4 or More RingsLactams, MacrocyclicLeucinepibrentasvirProlinePyrrolidinesQuinoxalinesRibavirinSofosbuvirSulfonamidesvelpatasvirglecaprevir/pibrentasvirhepatitis C virusretreatmentsofosbuvir/velpatasvir plus ribavirin

Identifiers

PMID34024853
PMCPMC8627798
OpenAlexW3164686734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.